Cargando…
PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431613/ http://dx.doi.org/10.1097/01.HS9.0000850912.43010.d3 |
| _version_ | 1784780103612366848 |
|---|---|
| author | Mateos, M. V. Bahlis, N. Costa, L. Perrot, A. Pei, L. Rubin, M. Lantz, K. Sun, W. Jaffe, M. Kobos, R. Nooka, A. |
| author_facet | Mateos, M. V. Bahlis, N. Costa, L. Perrot, A. Pei, L. Rubin, M. Lantz, K. Sun, W. Jaffe, M. Kobos, R. Nooka, A. |
| author_sort | Mateos, M. V. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431613 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94316132022-08-31 PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Mateos, M. V. Bahlis, N. Costa, L. Perrot, A. Pei, L. Rubin, M. Lantz, K. Sun, W. Jaffe, M. Kobos, R. Nooka, A. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431613/ http://dx.doi.org/10.1097/01.HS9.0000850912.43010.d3 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Mateos, M. V. Bahlis, N. Costa, L. Perrot, A. Pei, L. Rubin, M. Lantz, K. Sun, W. Jaffe, M. Kobos, R. Nooka, A. PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2020: majestec-3: randomized, phase 3 study of teclistamab plus daratumumab versus dpd or dvd in patients with relapsed/refractory multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431613/ http://dx.doi.org/10.1097/01.HS9.0000850912.43010.d3 |
| work_keys_str_mv | AT mateosmv pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT bahlisn pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT costal pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT perrota pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT peil pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT rubinm pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT lantzk pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT sunw pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT jaffem pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT kobosr pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma AT nookaa pb2020majestec3randomizedphase3studyofteclistamabplusdaratumumabversusdpdordvdinpatientswithrelapsedrefractorymultiplemyeloma |